Cara Ann East
Interventional Cardiology · Dallas, TXNPI 1770530420
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,288 of the $41,092 with a category attached, or 64.0%. Medtronic accounts for 83.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $13,846 and has fallen 80.2% since, to $2,748 in 2025.
Across 179 payments — averaging $229.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$34K
- Eli Lilly$3K
- Novartis$2K
- Amgen$588
- E.r. Squibb & Sons, L.L.C.$229
- Kaneka Medical America LLC$181
- plus $816 from 11 others
Across 728 payments — averaging $4169.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.8M
- Amgen$429K
- Eli Lilly$405K
- Esperion Therapeutics, Inc.$160K
- Boehringer Ingelheim International GmbH$144K
- Novo Nordisk AS$53K
- plus $66K from 5 others
What the payments were for
- Consulting fees$4751%
- Speaking & faculty fees$26,28864%
- Travel & lodging$9,70124%
- Food & beverage$4,59111%
- Education$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 73 | $34,289 |
| Eli Lilly | 32 | $2,867 |
| Novartis | 15 | $2,122 |
| Amgen | 14 | $588 |
| E.r. Squibb & Sons, L.L.C. | 9 | $229 |
| Kaneka Medical America LLC | 1 | $181 |
| Amarin Pharma, Inc. | 12 | $174 |
| Regeneron Healthcare Solutions, Inc. | 5 | $151 |
| Novo Nordisk | 2 | $128 |
| Novo Nordisk AS | 1 | $97 |
| Johnson & Johnson | 4 | $72 |
| Boehringer Ingelheim | 3 | $63 |
| AstraZeneca | 3 | $42 |
| Tactile Systems Technology Inc | 1 | $36 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $28 |
| Pfizer | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPLICITY G3$3,627
- LEQVIO$1,782
- RESOLUTE ONYX$792
- Repatha$112
How this compares
$41,092 in reported general payments places this provider in the 85th percentile of 686 interventional cardiology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 18 | $11,943 |
| Rosuvastatin Calcium | 34 | $315 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 14 | $177 |
| Metoprolol Succinate | 14 | $126 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Dallas
- Robert StolerDallas$587K
- Byung ParkDallas$236K
- James ChoiDallas$211K
- Tony DasDallas$187K
- Kenneth JohnsonDallas$113K
- Srinivas YallapragadaDallas$99K
- Wally OmarDallas$84K
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- Jeffrey CarrTyler$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.